Zoonotic infections by avian influenza virus: changing global epidemiology, investigation, and control
Avian influenza virus continues to pose zoonotic, epizootic, and pandemic threats worldwide, as exemplified by the 2020–23 epizootics of re-emerging H5 genotype avian influenza viruses
Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection
Respiratory syncytial virus (RSV) infection can cause severe respiratory illness in older adults.
Cow’s Milk Containing Avian Influenza A(H5N1) Virus — Heat Inactivation and Infectivity in Mice
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein
The development of a universal influenza virus vaccine, to protect against both seasonal and pandemic influenza A viruses, is a long-standing public health goal.
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Article
Scientific Papers
Influenza H5N1 and H1N1 viruses remain infectious in unpasteurized milk on milking machinery surfaces
Article
News
Scientific Papers
US Public Health Preparedness and Response to Highly Pathogenic Avian Influenza A(H5N1) Viruses
What is the pandemic potential of avian influenza A(H5N1)?
On March 25, 2024, a national authority in Viet Nam notified WHO of a case of human infection with highly pathogenic avian influenza. Then on April 1, a second but unrelated human infection with (H5N1virus was reported in Texas, USA.
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
Safe and effective vaccines against SARS-CoV-2 were developed in less than 1 year.
Wastewater testing finds H5N1 avian flu in 9 Texas cities
Researchers who sequenced viruses from wastewater samples from 10 Texas cities found H5N1 avian flu virus in 9 of them, sometimes at levels that rivaled seasonal flu.
Consensus sequences for U.S. H5N1 clade 2.3.4.4b (GISAID)
Defining the balance between optimal immunity and immunopathology in influenza virus infection
Influenza A viruses remain a global threat to human health, with continued pandemic potential.
